1Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of primary sclerosing cholangitis with HLADRw52a. N Engl J Med 1990; 322:1842-1844.
2Mehal WZ, Lo YM, Wordsworth BP, Neuberger JM, Hubscher SC, Fleming KA, Chapman RW. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis.Gastroenterology 1994; 106:160-167.
3Duerr RH, Targan SR, Landers CJ, Larusso NF, Lindsay KL,Wiesner RH, Shanahan F. Neutrophil cytoplasmic antibodies:a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100:1385-1391.
4Zauli D, Schrumpf E, Crespi C, Cassani F, Fausa O, Aadland E. An autoantibody profile in primary sclerosing cholangitis. J Hepatol 1987; 5:14-18.
6Wiesner RH, Larusso NF, Ludwig J, Dickson ER. Comparison of the clinicopathologic features of primary sclerosing cholangifts and primary biliary cirrhosis. Gastroenterology 1985; 88:108-114.
7Bodenheimer HC Jr, Larusso NF, Thayer WR Jr, Charland C,Staples PJ, Ludwig J. Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatoloxy 1983; 3:150-154.
9Brinch L, Teisberg P, Schrumpf E, Akesson I. The in vivo metabolism of C3 in hepatobiliary disease associated with ulcerative colitis. Scand J Gastroenterol 1982; 17:523-527.
10Ludwig J, Barham SS, Larusso NF, Elveback LR, Wiesner RH,McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1:632-640.
9Mchdez,SanchezN, Chavez et al, Aspectos moleculares de Las enfermedades colestasicas del higado New molecular features of Cholestatie, diseases of the liver [ J ]. Rer Lnvest Clin , 2003,55 (5) : 546
10Vacca M,Krawczyk M,Petruzzelli M,et al . Current treatments of primary sclerosing cholangitis [J]. Curr Med C hem,2007,14 (19): 2081-2094.
